by Maria Zannes | Jul 9, 2024 | Press Releases
Sales of CyPath® Lung tests continue to accelerate as sales team expands customer base of pulmonology practices SAN ANTONIO, TX (July 9, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for...
by Maria Zannes | Jun 12, 2024 | Press Releases
Sales of CyPath® Lung tests, onboarding of pulmonology practices ahead of forecasts SAN ANTONIO, TX (June 12, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection...
by Maria Zannes | May 15, 2024 | Press Releases
Expanded, experienced sales team more than doubles number of physician practices ordering CyPath® Lung test year-to-date More than 547% annualized growth rate for CyPath® Lung orders in first four months of 2024 over full-year 2023, leading to 35% increase in original...
by Maria Zannes | May 2, 2024 | Press Releases
SAN ANTONIO, Texas (May 2, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) shares recent Company news. CyPath® Lung Sales Ramp Up Month over Month Sales of CyPath® Lung, our noninvasive diagnostic test for the early detection of lung cancer, continue...
by Maria Zannes | Apr 24, 2024 | Press Releases
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth Collaboration with the US Department of Defense’s largest military health organization underway SAN ANTONIO, Texas (April 24, 2024) – bioAffinity Technologies,...
by Maria Zannes | Apr 9, 2024 | Press Releases
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening SAN ANTONIO, Texas (April 9, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) , a biotechnology company focused on the need for...
